The Potential Impact of Tislelizumab on First-Line ESCC Treatment

Drs Saba and Yoon reflect on how the potential FDA approval and availability of tislelizumab might change first-line ESCC treatment paradigms in the future.

Related Videos
Experts on solid tumors
Experts on solid tumors
Experts on solid tumors
Experts on solid tumors